The radiopharmaceutical developer expanded its reach, acquiring R&D, isotope production, manufacturing, and distribution.

The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

JP Morgan CEO Jamie Dimon said businesses are "encouraged by expectations for a more pro-growth agenda" heading into 2025.

JP Morgan’s James Sullivan says that China's muted growth outlook should not bar investors from wading into the markets there ...

The JP Morgan Healthcare Conference will show us many examples of how AI is affecting Healthcare. Cerebras and Nvidia are ...

JPMorgan Chase & Co.'s Chief Executive Jamie Dimon told analysts on Wednesday he plans to stay in the job "for a few more ...

Morgan Stanley reports strong Q4 results, beating expectations for EPS and revenue. Analyst expects outperformance and ...

Banking heavyweight JP Morgan Australia chair Robert Priestley has refused to back Carlton Football Club president Luke ...

Expected Solana and XRP ETFs could attract sizable investment, JP Morgan analysts said, but it's unlikely they'll match the ...

Fintel reports that on January 17, 2025, JP Morgan downgraded their outlook for Lucky Strike Entertainment (NYSE:LUCK) from ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...

Koreas biotech firms strive for growth amid investment challenges at JP Morgan event K-Bio executives highlight new ...